February 21, 2023

MultiplexDX is listed among the top Slovak startups to watch

Innovate Slovakia, an initiative focused on showcasing the best of the startup ecosystem in Slovakia, made a list of promising tech startups to watch in 2023 and put MultiplexDX on the list.

One of the initiative's main goals is to show successful Slovak companies with innovative solutions which operate on the market or get acquired, as well as new rising tech stars. Moreover, those companies might illustrate a new turn in our economy oriented toward the knowledge economy.

For the full list, check their website here.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News